| Literature DB >> 14592494 |
Lisa A Hasvold1, Weibo Wang, Stephen L Gwaltney, Todd W Rockway, Lissa T J Nelson, Robert A Mantei, Stephen A Fakhoury, Gerard M Sullivan, Qun Li, Nan-Horng Lin, Le Wang, Haiying Zhang, Jerome Cohen, Wen-Zhen Gu, Kennan Marsh, Joy Bauch, Saul Rosenberg, Hing L Sham.
Abstract
Farnesyltransferase inhibitors (FTIs) have been developed as potential anti-cancer agents due to their efficacy in blocking malignant growth in a variety of murine models of human tumors. To that end, we have developed a series of pyridone farnesyltransferase inhibitors with potent in vitro and cellular activity. The synthesis, SAR and biological properties of these compounds will be discussed.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14592494 DOI: 10.1016/j.bmcl.2003.08.058
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823